FDA Approves Kymriah to Treat Certain R/R Patients with Large B-Cell Lymphoma

On May 1, 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma. 

Read the company press release.

Read FDA announcement.

Posted 5/1/2018